A Pharmacist's Query Avoiding Exacerbation of Adverse Effects in a Patient with Acyclovir Encephalopathy: A Case Report
We report a haemodialysis patient with end-stage renal failure whom a pharmacist aided in the management of acyclovir (ACV) encephalopathy, which may have been related to valacyclovir hydrochloride (VACV) administered without sufficient dose reduction. The patient 78 years was admitted with a tentat...
Saved in:
| Published in | YAKUGAKU ZASSHI Vol. 142; no. 7; pp. 771 - 774 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
公益社団法人 日本薬学会
01.07.2022
Pharmaceutical Society of Japan |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0031-6903 1347-5231 1347-5231 |
| DOI | 10.1248/yakushi.21-00237 |
Cover
| Abstract | We report a haemodialysis patient with end-stage renal failure whom a pharmacist aided in the management of acyclovir (ACV) encephalopathy, which may have been related to valacyclovir hydrochloride (VACV) administered without sufficient dose reduction. The patient 78 years was admitted with a tentative diagnosis of varicella zoster viral meningitis. A pharmacist suspected ACV encephalopathy related to excessive VACV administration and raised a query with the attending physician. According to the pharmacist's proposal, ACV administration was discontinued and continuous hemodiafiltration (CHDF) was performed. On day 5 of hospitalisation, the consciousness disorder was improved. In this report, we showed the detailed CHDF conditions of the present case, and the contribution of a pharmacist to treating and avoiding ACV encephalopathy was discussed. |
|---|---|
| AbstractList | We report a haemodialysis patient with end-stage renal failure whom a pharmacist aided in the management of acyclovir (ACV) encephalopathy, which may have been related to valacyclovir hydrochloride (VACV) administered without sufficient dose reduction. The patient 78 years was admitted with a tentative diagnosis of varicella zoster viral meningitis. A pharmacist suspected ACV encephalopathy related to excessive VACV administration and raised a query with the attending physician. According to the pharmacist's proposal, ACV administration was discontinued and continuous hemodiafiltration (CHDF) was performed. On day 5 of hospitalisation, the consciousness disorder was improved. In this report, we showed the detailed CHDF conditions of the present case, and the contribution of a pharmacist to treating and avoiding ACV encephalopathy was discussed.We report a haemodialysis patient with end-stage renal failure whom a pharmacist aided in the management of acyclovir (ACV) encephalopathy, which may have been related to valacyclovir hydrochloride (VACV) administered without sufficient dose reduction. The patient 78 years was admitted with a tentative diagnosis of varicella zoster viral meningitis. A pharmacist suspected ACV encephalopathy related to excessive VACV administration and raised a query with the attending physician. According to the pharmacist's proposal, ACV administration was discontinued and continuous hemodiafiltration (CHDF) was performed. On day 5 of hospitalisation, the consciousness disorder was improved. In this report, we showed the detailed CHDF conditions of the present case, and the contribution of a pharmacist to treating and avoiding ACV encephalopathy was discussed. We report a haemodialysis patient with end-stage renal failure whom a pharmacist aided in the management of acyclovir (ACV) encephalopathy, which may have been related to valacyclovir hydrochloride (VACV) administered without sufficient dose reduction. The patient 78 years was admitted with a tentative diagnosis of varicella zoster viral meningitis. A pharmacist suspected ACV encephalopathy related to excessive VACV administration and raised a query with the attending physician. According to the pharmacist's proposal, ACV administration was discontinued and continuous hemodiafiltration (CHDF) was performed. On day 5 of hospitalisation, the consciousness disorder was improved. In this report, we showed the detailed CHDF conditions of the present case, and the contribution of a pharmacist to treating and avoiding ACV encephalopathy was discussed. |
| Author | 黒川, 直弘 松原, 亜紀 元木, 貴大 芳地, 一 山口, 佳津騎 田井, 達也 新村, 航 小坂, 信二 渡邊, 政博 田中, 裕章 |
| Author_xml | – sequence: 1 fullname: 渡邊, 政博 organization: 就実大学薬学部薬学科 – sequence: 1 fullname: 山口, 佳津騎 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 黒川, 直弘 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 松原, 亜紀 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 芳地, 一 organization: 徳島文理大学香川薬学部医療薬学講座 – sequence: 1 fullname: 田中, 裕章 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 田井, 達也 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 小坂, 信二 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 新村, 航 organization: 香川大学医学部附属病院薬剤部 – sequence: 1 fullname: 元木, 貴大 organization: 香川大学医学部附属病院薬剤部 |
| BookMark | eNo9UU2P0zAQtdAiUZa9c_QNLlnGn0m5RVV3F2klFgRny3GcxiW1i-10yb_HpSvmMO8wb948zXuLrnzwFqH3BG4J5c2nRf-a0-huKakAKKtfoRVhvK4EZeQKrQAYqeQa2Bt0k5LrCqeUIM0KPbf4adTxoI1L-UPC32YbF9yeguud3-HtH21s7HR2weMw4LY_2Zgs3g6DNTlh57HGT2VsfcbPLo-4NYuZwslFvPXGHkc9haPO4_IZt3ijy-p3ewwxv0OvBz0le_OC1-jn3fbH5qF6_Hr_ZdM-VnsmOKka3UgGvFkT6CWnTS247Lo1pwQYs1CwEaarBy1lBxpqEEQbIMZCJ2UvgV2jjxfdYwy_Z5uyOrhk7DRpb8OcFJWNACYYI4V6f6EebO9M8e0n563ahzn6YlGZVJ__vFO0vE8B4RTqAkJBXZNz47wYkuJ89OGitE9Z76w6RnfQcVE6Zmcmq17iUkVC1f86LQLn4P5TTAlF7TX7C50Dkl8 |
| ContentType | Journal Article |
| Copyright | 2022 The Pharmaceutical Society of Japan |
| Copyright_xml | – notice: 2022 The Pharmaceutical Society of Japan |
| CorporateAuthor | Shujitsu University Tokushima Bunri University School of Pharmacy bDepartment of Pharmacology and (cKagawa School of Pharmaceutical Sciences aDepartment of Pharmacy Kagawa University Hospital |
| CorporateAuthor_xml | – name: Kagawa University Hospital – name: bDepartment of Pharmacology – name: aDepartment of Pharmacy – name: Tokushima Bunri University – name: School of Pharmacy – name: Shujitsu University – name: and (cKagawa School of Pharmaceutical Sciences |
| DBID | 7X8 |
| DOI | 10.1248/yakushi.21-00237 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5231 |
| EndPage | 774 |
| ExternalDocumentID | cs7yakug_2022_014207_015_0771_07744042650 article_yakushi_142_7_142_21_00237_article_char_ja |
| GroupedDBID | .55 123 29R 2WC ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH MOJWN OVT P2P RJT RNS RZJ X7M XSB 7X8 |
| ID | FETCH-LOGICAL-j3541-8a863048910d64287546bb9421033e042185cb7fa66b0a07051ac01ce0b66d603 |
| ISSN | 0031-6903 1347-5231 |
| IngestDate | Fri Jul 11 03:16:40 EDT 2025 Thu Jul 10 16:15:08 EDT 2025 Wed Sep 03 06:31:07 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j3541-8a863048910d64287546bb9421033e042185cb7fa66b0a07051ac01ce0b66d603 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/yakushi/142/7/142_21-00237/_article/-char/ja |
| PQID | 2685035331 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_2685035331 medicalonline_journals_cs7yakug_2022_014207_015_0771_07744042650 jstage_primary_article_yakushi_142_7_142_21_00237_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20220701 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: 20220701 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | YAKUGAKU ZASSHI |
| PublicationTitleAlternate | 薬学雑誌 |
| PublicationYear | 2022 |
| Publisher | 公益社団法人 日本薬学会 Pharmaceutical Society of Japan |
| Publisher_xml | – name: 公益社団法人 日本薬学会 – name: Pharmaceutical Society of Japan |
| References | 9) Bleyzac N., Barou P., Massenavette B., Contamin B., Maire P., Berthier J. C., Aulagner G., Ther. Drug Monit., 21, 520-525 (1999). 13) Hara K., Suyama K., Itoh H., Nagashima S., Drug Metab. Pharmacokinet., 23, 306-312 (2008). 17) Helldén A., Odar-Cederlöf I., Diener P., Barkholt L., Medin C., Svensson J. O., Säwe J., Ståhle L., Nephrol. Dial. Transplant., 18, 1135-1141 (2003). 3) Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J., Antimicrob. Agents Chemother., 39, 2759-2764 (1995). 11) Yamamoto R., Nakayama Y., Araki M., Mine H., Hosokawa Y., Yamanaka M., Bulletin of Takamatsu Red Cross Hospital, 5, 40-44 (2017). 4) Wang L. H., Schultz M., Weller S., Smiley M. L., Blum M. R., Antimicrob. Agents Chemother., 40, 80-85 (1996). 12) Paulo M., Steven G., Oscar L., Harvey K., James C., Paul L., Clin. Pharmacol. Ther., 30, 662-672 (1981). 6) Helldén A., Lycke J., Vander T., Svensson J. O., Odar-Cederlöf I., Ståhle L., J. Antimicrob. Chemother., 57, 945-949 (2006). 15) Izumi A., Sakai K., Tamura Y., J. Jpn. Soc. Emerg. Med., 20, 763-768 (2017). 10) Kawabe Matsukawa M., Suzuki Y., Ikuma D., Suwabe T., Uesaka Y., Sugimoto I., Rinsho Shinkeigaku, 59, 834-839 (2019). 1) Gunness P., Aleksa K., Bend J., Koren G., Transl. Res., 158, 290-301 (2011). 8) Strumia S., De Mitri P., Bionda E., Eur. J. Neurol., 11, 68-69 (2004). 5) Asahi T., Tsutsui M., Wakasugi M., Tange D., Takahashi C., Tokui K., Okazawa S., Okudera H., Eur. J. Neurol., 16, 457-460 (2009). 14) Yamamoto T., Hisaka A., Suzuki H., Jpn. J. Nephrol. Pharmacother., 3, 3-19 (2014). 2) Furukubo T., Hirata S., Ota M., Fujita M., Izumi S., Yamakawa T., Jpn. J. Pharm. Health Care Sci., 30, 547-552 (2004). 16) Sagawa N., Tsurutani Y., Nomura K., Okuyama T., Kondou M., Sata A., Miyao M., Mizuno Y., Jpn. J. Geriatr., 51, 581-585 (2014). 7) Rivkin A., Ann. Pharmacother., 37, 1913 (2003). |
| References_xml | – reference: 4) Wang L. H., Schultz M., Weller S., Smiley M. L., Blum M. R., Antimicrob. Agents Chemother., 40, 80-85 (1996). – reference: 14) Yamamoto T., Hisaka A., Suzuki H., Jpn. J. Nephrol. Pharmacother., 3, 3-19 (2014). – reference: 10) Kawabe Matsukawa M., Suzuki Y., Ikuma D., Suwabe T., Uesaka Y., Sugimoto I., Rinsho Shinkeigaku, 59, 834-839 (2019). – reference: 3) Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J., Antimicrob. Agents Chemother., 39, 2759-2764 (1995). – reference: 12) Paulo M., Steven G., Oscar L., Harvey K., James C., Paul L., Clin. Pharmacol. Ther., 30, 662-672 (1981). – reference: 17) Helldén A., Odar-Cederlöf I., Diener P., Barkholt L., Medin C., Svensson J. O., Säwe J., Ståhle L., Nephrol. Dial. Transplant., 18, 1135-1141 (2003). – reference: 11) Yamamoto R., Nakayama Y., Araki M., Mine H., Hosokawa Y., Yamanaka M., Bulletin of Takamatsu Red Cross Hospital, 5, 40-44 (2017). – reference: 6) Helldén A., Lycke J., Vander T., Svensson J. O., Odar-Cederlöf I., Ståhle L., J. Antimicrob. Chemother., 57, 945-949 (2006). – reference: 7) Rivkin A., Ann. Pharmacother., 37, 1913 (2003). – reference: 9) Bleyzac N., Barou P., Massenavette B., Contamin B., Maire P., Berthier J. C., Aulagner G., Ther. Drug Monit., 21, 520-525 (1999). – reference: 1) Gunness P., Aleksa K., Bend J., Koren G., Transl. Res., 158, 290-301 (2011). – reference: 15) Izumi A., Sakai K., Tamura Y., J. Jpn. Soc. Emerg. Med., 20, 763-768 (2017). – reference: 5) Asahi T., Tsutsui M., Wakasugi M., Tange D., Takahashi C., Tokui K., Okazawa S., Okudera H., Eur. J. Neurol., 16, 457-460 (2009). – reference: 2) Furukubo T., Hirata S., Ota M., Fujita M., Izumi S., Yamakawa T., Jpn. J. Pharm. Health Care Sci., 30, 547-552 (2004). – reference: 13) Hara K., Suyama K., Itoh H., Nagashima S., Drug Metab. Pharmacokinet., 23, 306-312 (2008). – reference: 8) Strumia S., De Mitri P., Bionda E., Eur. J. Neurol., 11, 68-69 (2004). – reference: 16) Sagawa N., Tsurutani Y., Nomura K., Okuyama T., Kondou M., Sata A., Miyao M., Mizuno Y., Jpn. J. Geriatr., 51, 581-585 (2014). |
| SSID | ssib002222518 ssib002484306 ssib001136365 ssib002223935 ssib002484304 ssib002484305 ssib000959844 ssib002822080 ssib003105265 ssib023161479 ssj0023355 ssib000576198 ssib002499502 ssib003105266 ssib000937675 ssib000972830 ssib001536036 ssib002222551 ssib058494605 ssib058494604 |
| Score | 2.3657422 |
| Snippet | We report a haemodialysis patient with end-stage renal failure whom a pharmacist aided in the management of acyclovir (ACV) encephalopathy, which may have been... |
| SourceID | proquest medicalonline jstage |
| SourceType | Aggregation Database Publisher |
| StartPage | 771 |
| SubjectTerms | acyclovir encephalopathy adverse effect pharmacist |
| Title | A Pharmacist's Query Avoiding Exacerbation of Adverse Effects in a Patient with Acyclovir Encephalopathy: A Case Report |
| URI | https://www.jstage.jst.go.jp/article/yakushi/142/7/142_21-00237/_article/-char/ja http://mol.medicalonline.jp/en/journal/download?GoodsID=cs7yakug/2022/014207/015&name=0771-0774e https://www.proquest.com/docview/2685035331 |
| Volume | 142 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | YAKUGAKU ZASSHI, 2022/07/01, Vol.142(7), pp.771-774 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcYe5k0TfvUYB_ypIk9hLDEdpywp0VTERuMMalo8GQ5jqEpkExJA0v_-p2TNAkfD2wPdVvXsercL-ff2b47hN4HyotcqmLbg9nAZpTHdqS1Y6vI3-Qx0-qYGAfn73t8-4B9O_QOl5bmQ--SWbSh5rf6lfyPVKEO5Gq8ZP9Bsl2nUAGfQb5QgoShvJOMQ2u_iTydGM8Nv7B-ljqvrPAiS2pfldEfqeC2daywzr5caGvUHuJIUkuaIP3GJ7JZkQ1Vpc6yiyS3RsadcSLPMpOzuGod2GHKayn7kNQeydPyBF7WHJj4JOkXA-qTAmM5K8qq0_5H8lyemAwszVmOeZlmeXfJTplnp_JSNno_myR51i0BTZL0vKyzIlm_5Ezm5XDBgvSHWxc6ljLf2L9Nlb6lbqGYGRkg0B-oWb9J23JD_RNmXBoqGDGMdoO4tqEkfj_VLbb3936IrYPdXTEeHY7vofsE-qu3-L_u9FTSpZzyK6HfGB2arvX367_zztintM642w2s3SKHZh-v_z8gP1MwBUyMh4fnzfZcEyblBj-oSc_4MXrUWis4bKD3BC1N5VO01oKuWsfj3nuvWMdreL8PhF49Q5ch7vH5ocA1OvECnXiITpwd4xaduEUnTlIscYtObNCJO3Tiq-j8hENssIkbbD5HB1uj8Zdtu030YU-px1w7kAGHexsAdY2NPex7jEfRJiOuQ6mGaQVIJSiPY8l55EiYpDxXKsdV2ok4j7lDX6DlNEv1S4SJE2vi-FLHsc9YQAOlgAtsKrhGMkXZCgqbey1-N9FcRPv0ilYqYAsT4dclcUUtn66JcYQUU7mCPl8Rk2hVQiFU4ZtuToTBvXCgE8eHN084gDBTmGicBIyiFfRuIVkB-txs0slUZ2UhCA88h4IR5q7eoc0r9KB_xF6j5Vle6jfAkmfR2xrOfwHc3bnr |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Pharmacist%27s+Query+Avoiding+Exacerbation+of+Adverse+Effects+in+a+Patient+with+Acyclovir+Encephalopathy%3A+A+Case+Report&rft.jtitle=Yakugaku+zasshi&rft.au=Tai%2C+Tatsuya&rft.au=Yamaguchi%2C+Kazunori&rft.au=Kurokawa%2C+Naohiro&rft.au=Shinmura%2C+Wataru&rft.date=2022-07-01&rft.issn=1347-5231&rft.eissn=1347-5231&rft.volume=142&rft.issue=7&rft.spage=771&rft_id=info:doi/10.1248%2Fyakushi.21-00237&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6903&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6903&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6903&client=summon |